- Home
- FOXF vs AVXL Comparison
FOXF vs AVXL Comparison
Compare FOXF & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXF
- AVXL
- Stock Information
- Founded
- FOXF 2007
- AVXL 2004
- Country
- FOXF United States
- AVXL United States
- Employees
- FOXF N/A
- AVXL N/A
- Industry
- FOXF Motor Vehicles
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FOXF Consumer Discretionary
- AVXL Health Care
- Exchange
- FOXF Nasdaq
- AVXL Nasdaq
- Market Cap
- FOXF 1.2B
- AVXL 956.7M
- IPO Year
- FOXF N/A
- AVXL N/A
- Fundamental
- Price
- FOXF $26.02
- AVXL $8.78
- Analyst Decision
- FOXF Buy
- AVXL Strong Buy
- Analyst Count
- FOXF 7
- AVXL 2
- Target Price
- FOXF $34.86
- AVXL $44.00
- AVG Volume (30 Days)
- FOXF 390.8K
- AVXL 944.5K
- Earning Date
- FOXF 10-30-2025
- AVXL 08-12-2025
- Dividend Yield
- FOXF N/A
- AVXL N/A
- EPS Growth
- FOXF N/A
- AVXL N/A
- EPS
- FOXF N/A
- AVXL N/A
- Revenue
- FOXF $1,441,852,000.00
- AVXL N/A
- Revenue This Year
- FOXF $8.61
- AVXL N/A
- Revenue Next Year
- FOXF $6.08
- AVXL N/A
- P/E Ratio
- FOXF N/A
- AVXL N/A
- Revenue Growth
- FOXF 7.16
- AVXL N/A
- 52 Week Low
- FOXF $17.95
- AVXL $5.03
- 52 Week High
- FOXF $44.27
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- FOXF 36.10
- AVXL 39.78
- Support Level
- FOXF $27.30
- AVXL $8.85
- Resistance Level
- FOXF $28.98
- AVXL $9.69
- Average True Range (ATR)
- FOXF 1.02
- AVXL 0.55
- MACD
- FOXF -0.32
- AVXL -0.02
- Stochastic Oscillator
- FOXF 8.14
- AVXL 1.82
About FOXF Fox Factory Holding Corp.
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.